Keywords: Roche, Biogen Idec, Ocrelizumab, Rheumatoid arthritis

Roche/Biogen drop development of ocrelizumab in rheumatoid arthritis

Article | 19 May 2010

Print This

In an announcement that probably comes as no surprise, Swiss drug major Roche and partner USA-based Biogen Idec have decided ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in